Trial · NCT00936741

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741, Phase 3, Completed, Corcept Therapeutics; results first posted 2014-04-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome. Trials, record NCT00936741. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00936741

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
NCT number: NCT00936741
Status: Completed
Phases: Phase 3
Enrollment: 30 participants, actual
Lead sponsor: Corcept Therapeutics
Conditions: Cushing's Syndrome
Interventions: mifepristone
First posted: 2009-07-10
Last updated: 2014-04-02
Results first posted: 2014-04-02

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Adverse Events	Up to three years.	Subjects who received at least one dose of mifepristone were included in the safety analysis.
Secondary	The Long-term Benefit of Mifepristone Treatment in Cushing's Syndrome as Measured by Changes in the Score on the Physician's Global Assessment of Disease Severity	Up to three years.	The mean Investigator's rating of the change in subject's signs and symptoms of Cushing's syndrome from Baseline (Entry into C1073-415) to Endpoint on the Physician's Global Assessment of Disease Severity was ranked on a 9-point scale (9 = much worse, 7 = worse, 5 = no change, 3 = better, 1 = much better). Higher scores indicate more severe illness. Scoring was done at all visits except the 6 Week Follow-up visit; the final visit result (Endpoint) is reported here. The instruction was "Rate the change in the subject's signs and symptoms of Cushing's from Baseline (1 = much better to 9 = much worse)".

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Adverse Events	Up to three years.	Subjects who received one dose of study drug were included in the safety and ITT analyses.	participants	NUMBER
SECONDARY	The Long-term Benefit of Mifepristone Treatment in Cushing's Syndrome as Measured by Changes in the Score on the Physician's Global Assessment of Disease Severity	Up to three years.		units on a scale	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Participants With Adverse Events	Open-label		30		participants
The Long-term Benefit of Mifepristone Treatment in Cushing's Syndrome as Measured by Changes in the Score on the Physician's Global Assessment of Disease Severity	Open-label		3.3	Standard Deviation 1.74	units on a scale

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Open-label	30
Overall Study	COMPLETED	Open-label	21
Overall Study	NOT COMPLETED	Open-label	9

Source ClinicalTrials.gov

Adverse events109

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Adrenal insufficiency	Endocrine disorders	Mifepristone 300 to 1200 mg Daily	3	30	3
other	Abdominal pain upper	Gastrointestinal disorders	Mifepristone 300 to 1200 mg Daily	5	30	6
other	Nausea	Gastrointestinal disorders	Mifepristone 300 to 1200 mg Daily	15	30	29
other	Vomiting	Gastrointestinal disorders	Mifepristone 300 to 1200 mg Daily	7	30	14
other	Fatique	General disorders	Mifepristone 300 to 1200 mg Daily	12	30	14
other	Oedema peripheral	General disorders	Mifepristone 300 to 1200 mg Daily	7	30	10
other	Nasopharyngitis	Infections and infestations	Mifepristone 300 to 1200 mg Daily	6	30	7
other	Upper respiratory tract infection	Infections and infestations	Mifepristone 300 to 1200 mg Daily	6	30	7
other	Blood potassium decreased	Investigations	Mifepristone 300 to 1200 mg Daily	14	30	46
other	Thyroid function test abnormal	Investigations	Mifepristone 300 to 1200 mg Daily	6	30	6

1 to 10 of 109Source ClinicalTrials.gov

See all 109 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Mifepristone 300 to 1200 mg Daily
Total, other adverse events	Mifepristone 300 to 1200 mg Daily	30	30
Total, serious adverse events	Mifepristone 300 to 1200 mg Daily	18	30

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
25013998	DERIVED	PubMed
26507877	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00936741

GET https://conductscience.org/api/trials/v1/NCT00936741/events?page=2

API reference For AI assistants